Pritelivir是一种具有抗HSV活性的解旋酶-引发酶抑制剂。进行了两项人体质量平衡试验(多剂量试验和单剂量试验)以表征吸收,分布,新陈代谢,和排泄100毫克口服普利利韦联合单剂量14C-普利利韦。血,尿液,并在给药后26天收集粪便样本。普立利韦的血浆半衰期为63-67小时。总的来说,92%和66%的给药剂量在多剂量和单剂量试验中恢复,分别。单剂量后的低回收率(66%)最可能与所用的制剂有关。主要代谢途径是酰胺水解,导致氨基噻唑磺酰胺(ATS)和吡啶基苯乙酸(PPA)。在等离子体中,pritelivir,ATS,PPA,PPA-酰基葡糖苷酸占40.6%,9.4%,5.1%,和总放射性的0.2%。超过90%的药物相关物质在给药后624小时被消除。大多数在尿液中排泄(75%和77%),其次是粪便(16%和23%)。尿液中的主要成分是PPA-酰基葡糖苷酸(及其异构体),ATS,及其N-去甲基化异构体。在粪便中仅观察到少量代谢物。总之,普利利韦的主要代谢途径已被确定,主要排泄途径是肾脏。
Pritelivir is a helicase-primase inhibitor active against HSV. Two human mass balance trials (a multiple-dose trial and a single-dose trial) were performed to characterize the absorption, distribution, metabolism, and excretion of 100 mg oral pritelivir combined with a single microdose of 14C-pritelivir. Blood, urine, and feces samples were collected up to 26 days postdose. The plasma half-life of pritelivir was 63-67 hours. Overall, 92% and 66% of the administered dose was recovered in the multiple and single dose trials, respectively. The low recovery after the single dose (66%) was most likely related to the formulation used. The major metabolic pathway was amide hydrolysis leading to amino thiazole sulfonamide (ATS) and pyridinyl phenyl acetic acid (PPA). In plasma, pritelivir, ATS, PPA, and PPA-acyl glucuronide accounted for 40.6%, 9.4%, 5.1%, and 0.2% of total radioactivity. More than 90% of drug-related material was eliminated 624 hours postdose. The majority was excreted in urine (75% and 77%), followed by feces (16% and 23%). The main components in urine were PPA-acyl glucuronide (and its isomers), ATS, and its N-demethylated isomers. Only minor metabolites were observed in feces. In conclusion, the major metabolic pathways of pritelivir have been identified with the primary excretion route being renal.